Literature DB >> 24673802

Dynamic enhancement pattern of HCC smaller than 3 cm in diameter on gadoxetic acid-enhanced MRI: comparison with multiphasic MDCT.

Vivian Y Park1, Jin-Young Choi, Yong Eun Chung, Honsoul Kim, Mi-Suk Park, Joon Seok Lim, Ki Whang Kim, Myeong-Jin Kim.   

Abstract

BACKGROUND & AIMS: The dynamic enhancement pattern of HCCs smaller than 3 cm in diameter on gadoxetic acid-enhanced magnetic resonance imaging (MRI) have not been extensively investigated. We aimed to evaluate the dynamic enhancement patterns of small HCCs (≤3 cm) on gadoxetic acid-enhanced magnetic resonance imaging (MRI) and compare enhancement patterns with multiphasic multidetector computed tomography (MDCT) based on tumour cellular differentiation and size.
METHODS: We retrospectively included 55 patients with 67 surgically confirmed small HCCs (≤3 cm) who underwent multiphasic MDCT and gadoxetic acid-enhanced MRI. Dynamic enhancement patterns were analysed according to tumour cellular differentiation and size. Hepatobiliary phase images were also analysed to assess their additional value.
RESULTS: The proportion of small HCCs demonstrating the typical enhancement pattern differed depending on tumour cellular differentiation on both MRI (P = 0.001) and MDCT (P = 0.001), but differed depending on tumour size only on CT (P = 0.008). Gadoxetic acid-enhanced MRI more sensitively depicted the typical enhancement pattern than CT for all tumours (P = 0.001), for moderately or poorly differentiated HCCs (P = 0.021) and for HCCs ≤2 cm (P = 0.001). 80% of tumours with atypical enhancement could be diagnosed as HCC based on tumour size and hepatobiliary phase images.
CONCLUSIONS: On both gadoxetic acid-enhanced MRI and multiphasic CT, the dynamic enhancement patterns of small HCCs (≤3 cm) differed according to tumour cellular differentiation. Gadoxetic acid-enhanced MRI more frequently demonstrated the typical HCC enhancement pattern than CT in small HCCs.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  dynamic enhancement; gadoxetic acid; magnetic resonance imaging; multidetector computed tomography; small HCC

Mesh:

Substances:

Year:  2014        PMID: 24673802     DOI: 10.1111/liv.12550

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  15 in total

Review 1.  Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.

Authors:  Masao Omata; Ann-Lii Cheng; Norihiro Kokudo; Masatoshi Kudo; Jeong Min Lee; Jidong Jia; Ryosuke Tateishi; Kwang-Hyub Han; Yoghesh K Chawla; Shuichiro Shiina; Wasim Jafri; Diana Alcantara Payawal; Takamasa Ohki; Sadahisa Ogasawara; Pei-Jer Chen; Cosmas Rinaldi A Lesmana; Laurentius A Lesmana; Rino A Gani; Shuntaro Obi; A Kadir Dokmeci; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2017-06-15       Impact factor: 6.047

2.  Does a combined CT and MRI protocol enhance the diagnostic efficacy of LI-RADS in the categorization of hepatic observations? A prospective comparative study.

Authors:  Mohammad Abd Alkhalik Basha; Mohamad Zakarya AlAzzazy; Ayman F Ahmed; Hala Y Yousef; Samar Mohamad Shehata; Dena Abd El Aziz El Sammak; Talaat Fathy; Ahmed Ali Obaya; Eman H Abdelbary
Journal:  Eur Radiol       Date:  2018-01-24       Impact factor: 5.315

3.  Gadoxetic acid-enhanced MRI for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: can hypointensity on the late portal venous phase be used as an alternative to washout?

Authors:  Kyoung A Baek; Seung Soo Kim; Hyeong Cheol Shin; Jeong Ah Hwang; Seo-Youn Choi; Woong Hee Lee; Chan Ho Park; Hyoung Nam Lee; Nam Hun Heo
Journal:  Abdom Radiol (NY)       Date:  2020-09

Review 4.  Recent Advances in the Imaging Diagnosis of Hepatocellular Carcinoma: Value of Gadoxetic Acid-Enhanced MRI.

Authors:  Ijin Joo; Jeong Min Lee
Journal:  Liver Cancer       Date:  2015-12-18       Impact factor: 11.740

5.  Performance of adding hepatobiliary phase image in magnetic resonance imaging for detection of hepatocellular carcinoma: a meta-analysis.

Authors:  Jielin Pan; Wenjuan Li; Lingjing Gu; Chaoran Liu; Ke Zhang; Guobin Hong
Journal:  Eur Radiol       Date:  2022-05-17       Impact factor: 5.315

Review 6.  [Clinical relevance of the new S3 guideline on hepatocellular carcinoma and biliary tract cancer for practitioners].

Authors:  Sabrina Voesch; M Bitzer; N Malek
Journal:  Radiologe       Date:  2022-02-11       Impact factor: 0.635

Review 7.  JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan.

Authors:  Masatoshi Kudo; Osamu Matsui; Namiki Izumi; Hiroko Iijima; Masumi Kadoya; Yasuharu Imai; Takuji Okusaka; Shiro Miyayama; Kaoru Tsuchiya; Kazuomi Ueshima; Atsushi Hiraoka; Masafumi Ikeda; Sadahisa Ogasawara; Tatsuya Yamashita; Tetsuya Minami; Koichiro Yamakado
Journal:  Liver Cancer       Date:  2014-10       Impact factor: 11.740

8.  Gadoxetic acid-enhanced magnetic resonance imaging characteristics of hepatocellular carcinoma occurring in liver transplants.

Authors:  Mimi Kim; Tae Wook Kang; Woo Kyoung Jeong; Young Kon Kim; Seong Hyun Kim; Jong Man Kim; Dong Hyun Sinn; Min-Ji Kim; Sin-Ho Jung
Journal:  Eur Radiol       Date:  2016-12-12       Impact factor: 5.315

9.  Hyperintensity at fat spared area in steatotic liver on the hepatobiliary phase MRI.

Authors:  Emre Ünal; İlkay Sedakat İdilman; Ali Devrim Karaosmanoğlu; Mustafa Nasuh Özmen; Deniz Akata; Muşturay Karcaaltıncaba
Journal:  Diagn Interv Radiol       Date:  2019-11       Impact factor: 2.630

10.  CT features of hepatic epithelioid angiomyolipoma: differentiation from hepatocellular carcinoma in patients with noncirrhotic livers.

Authors:  Weihai Liu; Wenjie Liang
Journal:  Quant Imaging Med Surg       Date:  2018-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.